Physics

Internal medicine

Obesity

Diabetes mellitus

Incidence (geometry)

Biology

Optics

Cancer

Endocrinology

Oncology

Paleontology

Context (archaeology)

Pancreatic cancer

Medicine

Digestive and Liver Disease

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers worldwide. Most patients with PDAC are diagnosed with advanced stage, and the mean 5-year survival is as low as 7% [1]. Several comorbidities are associated with an increased risk of developing PDAC [2]. Some of them, such as diabetes, hypertension, obesity and chronic pancreatitis might also result in a lower overall survival (OS) [3]. In this context, it is particularly interesting to investigate the association between drugs used to treat such comorbidities and PDAC outcome.

Does chronic consumption of angiotensin-converting enzyme inhibitors affect survival after surgical resection of pancreatic ductal adenocarcinoma?